Study of Hepalatide in Chronic Hepatitis D(CHD) Patients

Inclusion Criteria:

• Male or female, 18-65 years old (both inclusive);
• HBsAg (+) and/or HBV DNA (+) for at least 6 months (clinically diagnosed as "chronichepatitis B");
• HDV-antibody (IgG/IgM) (+) and HDV RNA (+);
• 1×ULN <ALT<10×ULN；
• Patients with hepatitis B eligible to receive treatment with NAs according to currentguidelines for the diagnosis and treatment of hepatitis B;
• Patients who do not plan a pregnancy within two years (women who are not pregnant orlactating) and agree to take effective contraceptive measures throughout the treatmentperiod and within 3 months after the last dose;
• Patients who did not participate in any other clinical trials within 3 months;
• Patients with good compliance with the study protocol;
• Patients who understand and agree to sign an informed consent form.

Exclusion Criteria:

• Decompensated liver disease: Direct bilirubin > 1.2× ULN, prothrombin time > 1.2× ULN,and serum albumin < 35 g/L;
• Patients with abnormal results of routine hematology test: White blood cell count (WBC) < 3×109/L, neutrophil count < 1.5×109/L and platelet count < 60×109/L;
• Severely decompensated hepatic fiborosis or decompensated cirrhosis: Definitelydiagnosed decompensated cirrhosis by imaging examinations such as a Color Dopplerultrasound and CT of the abdomen or clinically diagnosed decompensated cirrhosis bythe investigator, or a Metavir fibrosis score of 4 on a liver biopsy sample, or aChild-Pugh score > 7 for liver function assessment;
• Patients who have any of the following conditions:

1. A history of decompensated liver disease (ascites, jaundice, hepaticencephalopathy, variceal bleeding);
2. A history of serious cardiovascular disease (including unstable or uncontrolledcardiovascular disease within 6 months);
3. Serious mental illness or a history of serious mental illness;
4. A history of organ transplantation;
5. Uncontrolled epilepsy, mental illness, or poorly controlled diabetes orhypertension;
6. Autoimmune disease, immune-related extrahepatic manifestations (vasculitis,purpura, arteritis nodosa, peripheral neuropathy, and glomerulonephritis),thyroid disease, malignant tumor, and receiving immunosuppressive therapy;
7. Underlying diseases such as severe infection, heart failure, chronic obstructivepulmonary disease, and other severe diseases;
8. A history of alcohol or drug abuse.

• Creatinine clearance < 60 mL/min;
• HAV/HCV/HEV/HIV co-infection;
• Resistance to or poor response to Entecavir;
• An allergic reaction to Entecavir;
• Patients who have used interferon within 3 months before the screening period;
• Previously received L47 or Bulevirtide;
• Women who have a positive pregnancy test;
• Patients who have other significantly abnormal results of laboratory or auxiliarytests and are unsuitable for this trial.